The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.
At least two early-access users, at Massachusetts General Hospital and at Weill Cornell, have explored the new platform for infectious disease testing.
The automated, whole-genome directional genomic hybridization system can measure de novo random, low-frequency, and complex structural variations.
In addition, Qiagen has partnered with Japan's SRL for companion diagnostic development, and its CareHPV test was added to the WHO list of prequalified IVDs.
The company is expecting that existing users from its technology access program are likely to purchase instruments when they become available later this year.
At the AGBT conference this week, the DNA synthesis discussed the new capture products and its overall business.
At AGBT, researchers described applications for rapid pathogen ID; evaluating DNA, RNA, and gene expression in one assay; and understanding tumor heterogeneity.
Validation results presented at the Association for Molecular Pathology meeting demonstrate that the test can be implemented clinically, replacing existing FISH and PCR assays.
Performed on the company's Safetube platform, GFC's Microscreen test uses DNA hybridization to detect biomarkers in methicillin-resistant Staphylococcus aureus.
Researchers used the approach to develop an assay to detect above-threshold triplet repeats in Huntington's disease, but also highlight a variety of other applications.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.